Protagonist Therapeutics Inc
PTGXNASDAQStock · Data from SEC EDGAR 13F · Held by 6 of 87 tracked investors
Protagonist Therapeutics Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation8
- Growth95
- Profitability95
- Quality74
- Debt100
- Stability23
- ✓Out of 100 USD of revenue, 29 USD is left as net profit.
- ✓It has more cash than debt.
- ✓Revenue grew 20.1% a year over 3 years.
- ✓The analysts' average target is 27% above the price.
- !The stock is expensive: you pay 137 USD for 1 USD of annual earnings.
- !In some year revenue fell sharply.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
ExpensiveFor 1 USD of annual earnings you pay 137.0 USD.
- P/E
- 137.0×
- P/S
- 32.4×
- EV/EBITDA
- 139.6×
Is the company growing?
GrowingRevenue over 3 years grew 20.1% a year. Last year 3,749.2%.
Does it make money?
ExcellentNet margin: 29.4%.
Is it financially healthy?
YesEarnings results
| Quarter | Reported | EPS | Analyst estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | 5 Aug 2026 | 2.29 | 2.11 | +8.5% |
| Mar 2026 | 5 May 2026 | 0.05 | -0.65 | +107.7% |
| Dec 2025 | 25 Feb 2026 | -0.69 | -0.53 | -30.2% |
| Sep 2025 | 6 Nov 2025 | -0.62 | -0.59 | -5.1% |
EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.
Chart PTGX
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
6SD Stanley Druckenmiller Duquesne Family Office | 0.49% |
JG Joel Greenblatt Gotham Asset Management | 0.01% |
KF Ken Fisher Fisher Investments | 0.01% |
Šn Švýcarská národní banka Swiss National Bank | 0.01% |
RD Ray Dalio Bridgewater Associates | 0% |
RB Ron Baron Baron Capital | 0% |
Frequently asked questions
How much is Protagonist Therapeutics Inc (PTGX) stock?
Protagonist Therapeutics Inc shares trade at $141.12, +0.57% over the last trading day. The price is delayed.
What is the market cap of Protagonist Therapeutics Inc?
The market cap of Protagonist Therapeutics Inc is about $9.1B and its price-to-earnings ratio (P/E) is 137.
Which big investors hold Protagonist Therapeutics Inc?
According to the latest 13F filings, 6 of 87 tracked investors hold Protagonist Therapeutics Inc, for example Stanley Druckenmiller, Joel Greenblatt, Ken Fisher.
When will Protagonist Therapeutics Inc report its next results?
The next earnings report of Protagonist Therapeutics Inc is expected on 5 Nov 2026.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.